Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ICVX

Icosavax (ICVX) Stock Price, News & Analysis

Icosavax logo

About Icosavax Stock (NASDAQ:ICVX)

Key Stats

Today's Range
$15.31
$15.31
50-Day Range
$15.31
$15.45
52-Week Range
$4.75
$16.10
Volume
N/A
Average Volume
1.22 million shs
Market Capitalization
$766.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Receive ICVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Icosavax and its competitors with MarketBeat's FREE daily newsletter.

ICVX Stock News Headlines

There is a little known company that is changing warfare
With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.
Vaxcyte Inc Ordinary Shares 5VA
NervGen Pharma Corp Ordinary Shares NGEN
Icosavax: Tender Offer With Contingent Value Right
Icosavax CVR Seems Fairly Valued
See More Headlines

ICVX Stock Analysis - Frequently Asked Questions

Icosavax, Inc. (NASDAQ:ICVX) posted its quarterly earnings data on Monday, November, 15th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.81. The company earned $1.83 million during the quarter, compared to the consensus estimate of $3.30 million.

Icosavax (ICVX) raised $150 million in an initial public offering on Thursday, July 29th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that Icosavax investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
11/15/2021
Today
11/17/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ICVX
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.00
High Stock Price Target
$28.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+82.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-91,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$580,000.00
Book Value
$5.47 per share

Miscellaneous

Free Float
34,767,000
Market Cap
$766.88 million
Optionable
Optionable
Beta
1.28
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:ICVX) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners